ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB - Get Free Report) shares passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $47.69 and traded as high as $47.96. ProShares Ultra Nasdaq Biotechnology shares last traded at $47.58, with a volume of 4,145 shares changing hands.
ProShares Ultra Nasdaq Biotechnology Stock Performance
The company's fifty day simple moving average is $47.53 and its two-hundred day simple moving average is $53.18. The stock has a market capitalization of $51.60 million, a P/E ratio of 21.19 and a beta of 1.63.
ProShares Ultra Nasdaq Biotechnology Cuts Dividend
The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 1st. Stockholders of record on Wednesday, March 26th were given a $0.1309 dividend. The ex-dividend date of this dividend was Wednesday, March 26th. This represents a $0.52 dividend on an annualized basis and a dividend yield of 1.12%.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in BIB. Jane Street Group LLC grew its position in ProShares Ultra Nasdaq Biotechnology by 8.4% during the third quarter. Jane Street Group LLC now owns 4,803 shares of the exchange traded fund's stock worth $306,000 after buying an additional 374 shares in the last quarter. Crowley Wealth Management Inc. acquired a new stake in shares of ProShares Ultra Nasdaq Biotechnology during the 4th quarter worth $51,000. Tower Research Capital LLC TRC increased its position in shares of ProShares Ultra Nasdaq Biotechnology by 31.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,326 shares of the exchange traded fund's stock worth $270,000 after purchasing an additional 1,266 shares during the period. Finally, IMC Chicago LLC acquired a new position in ProShares Ultra Nasdaq Biotechnology in the first quarter valued at about $1,080,000.
About ProShares Ultra Nasdaq Biotechnology
(
Get Free Report)
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Featured Articles
Before you consider ProShares Ultra Nasdaq Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProShares Ultra Nasdaq Biotechnology wasn't on the list.
While ProShares Ultra Nasdaq Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
